Metrika članka

  • citati u SCindeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:4
  • preuzimanja u poslednjih 30 dana:1
članak: 3 od 4  
Back povratak na rezultate
Vojnosanitetski pregled
2015, vol. 72, br. 6, str. 483-488
jezik rada: engleski
vrsta rada: izvorni naučni članak
objavljeno: 28/07/2015
doi: 10.2298/VSP140115014S
Srpska limfomska grupa - demografske karakteristike 257 ispitanika sa folikularnim limfomom
aKlinički centar Niš, Klinika za hematologiju i kliničku imunologiju
bKlinički centar Niš, Klinika za hematologiju i kliničku imunologiju + Univerzitet u Nišu, Medicinski fakultet
cKlinički centar Srbije, Beograd
dKlinički centar Srbije, Beograd + Univerzitet u Beogradu, Medicinski fakultet

e-adresa: okisim555@gmail.com

Sažetak

Uvod/Cilj. Folikularni limfom (FL), B-ćelijski tumor obič no je indolentnog kliničkog toka bolesti, ali u nekim slučajevima tok bolesti može biti veoma agresivan. Cilj istraživanja bio je da se utvrdi raspodela bolesnika u prognostičke grupe u odnosu na internacionalni prognostički indeks (IPI) i folikularni limfom internacionalni prognostični indeks (FLIPI) kriterijume, kao i da se odredi značaj klasifikovanja bolesnika u prognostičke grupe koje bi mogle potencijalno uticati na izbor modaliteta lečenja. Metode. Retrospektivno istraživanje izvedeno je na 257 bolesnika sa FL koji su dijagnostikovani od januara 2000. do aprila 2011. Rezultati. Na osnovu IPI prognostičkog indeksa, nizak rizik imalo je 153 (59,53%) bolesnika, srednje nizak rizik 57 (22,18%), srednje visok rizik 15 (5,84%), visoki rizik 9 (3,50%) bolesnika, a nepoznato je bilo svrstavanje 23 bolesnika sa dijagnozom folikularnog limfoma prema IPI. Na osnovu FLIPI prognostičkogi indeksa, nizak rizik imalo je 113 (43,97%), srednji 70 (27,24%), visoki rizik 51 (19,84%), a nepoznato je bilo svrstavanje 23 (8,95%) bolesnika. Na osnovu FLIPI 2 prognostičkog indeksa, nizak rizik imalo je 48 (18,68%), srednji 145 (56,42%), a visoki 41 (15,95%) bolesnika sa FL. Nepoznato je bilo svrstavanje 23 (8,95%) bolesnika. Prema IPI, FLIPI i FLIPI 2 bilo je bolesnika koji zahtevaju lečenje u svim prognostičkim grupama. Zaključak. FLIPI i FLIPI 2 efikasno grupišu bolesnike u grupu visokog rizika i pomažu pri odluci o lečenju za svakog pojedinačnog bolesnika.

Ključne reči

Reference

*** (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood, 89(11): 3909-18
Agarwal, A.M., Agarwal, N., Glenn, M.J., Lim, M.S. (2007) Blastic Transformation of Low-Grade Follicular Lymphoma. J Clin Oncol, 25(16): 2326-2328
Anderson, J.R., Armitage, J.O., Weisenburger, D.D. (1998) Epidemiology of the non-Hodgkin's lymphomas: Distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol, 9(7): 717-20
Anđelić, B., Mihaljević, B. (2010) Prognostic factors in follicular lymphoma. Acta clinica, vol. 10, br. 3, str. 49-62
Coiffier, B. (2005) First line treatment of follicilar lymphoma in the era of monoclonal antibodies. Clin Adv Hematol Ocol, 3(6): 484-91
Dave, S.S., Wright, G., Tan, B., Rosenwald, A., Gascoyne, R.D., i dr. (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med, 351(21): 2159-69
Dreyling, M., Ghielmini, M., Marcus, R., Salles, G., Vitolo, U. (2011) ESMO Guidelines Working Group. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up. Ann Oncol, 22(suppl 6): 59-63
Federico, M., Vitolo, U., Zinzani, P.L., Chisesi, T., Clo, V., Bellesi, G., Magagnoli, M., Liberati, M., Boccomini, C., Niscola, P., Pavone, V., Cuneo, A., Santini, G., Brugiatelli, M., Baldini, L., Rigacci, L., Resegotti, L. (2000) Prognosis of follicular lymphoma: A predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood, 95(3): 783-9
Federico, M., Bellei, M., Marcheselli, L., Luminari, S., Lopez-Guillermo, A., Vitolo, U., Pro, B., Pileri, S., Pulsoni, A., Soubeyran, P., i dr. (2009) Follicular lymphoma international prognostic index 2: A new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. Journal of clinical oncology, 27(27): 4555-62
Friedberg, J.W., Taylor, M.D., Cerhan, J.R., Flowers, C.R., Dillon, H., Farber, C.M., i dr. (2009) Follicular lymphoma in the United States: first report on the national LymphoCare study. J Oncol, 27(8): 120
Gilles, A.S. (2007) Clinical features, prognosis and treatment of follicular lymphoma. ASH Education Book, 2007(1): 216-25
Glas, A.M., Kersten, M.J., Delahaye, L.J.M.J., Witteveen, A.T., Kibbelaar, R.E., Velds, A., Wessels, L.F.A., Joosten, P., Kerkhoven, R.M., Bernards, R., van Krieken, J.H.J.M., Kluin, P.M., i dr. (2005) Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood, 105(1), 301-307
Horning, S.J. (1993) Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol, 20(5 Suppl 5): 75-88
Katzenberger, T., Ott, G., Klein, T., Kalla, J., Muller-Hermelinek, H.K., Ott, M.M. (2004) Cytogenetic alterations affecting bcl6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B cell component. Am J pathol, (165): 481-490
Kersten, M.J., de Jong, D., Raemaekers, JohnM.M., Kluin, P.M., Hagenbeek, A. (2004) Beyond the International Prognostic Index: New prognostic factors in follicular lymphoma and diffuse large-cell lymphomaA meeting report of the Second International Lunenburg Lymphoma Workshop. Hematol J, 5(3): 202-208
Mac, M.M.P., Hoppe, R.T. (1996) Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol, 14(4): 1282-90
Perea, G., Altés, A., Montoto, S., López-Guillermo, A., Domingo-Doménech, E., Fernández-Sevilla, A., Ribera, J.M., Grau, J., Pedro, C., Angel, H.J., Estany, C., Briones, J., Martino, R., Sureda, A., Sierra, J., Montserrat, E. (2005) Prognostic indexes in follicular lymphoma: A comparison of different prognostic systems. Annals of oncology, 16(9): 1508-13
Rosenbaum, C.A. (2007) Evolving paradigms in follicular lymphoma: Reevaluating prognostic factors and challenig treatments dogmas. Molecular Oncology Report, 1(2): 33-8
Salles, G., Seymour, J.F., Offner, F., López-Guillermo, A., Belada, D., Xerri, L., Feugier, P., Bouabdallah, R., Catalano, J.V., Brice, P., Caballero, D., Haioun, C. (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet, 377(9759): 42-51
Sehn, L.H. (2006) Optimal use of prognostic factors in non-Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program, 295-302
Solal-Céligny, P., Roy, P., Colombat, P., White, J., Armitage, J.O., Arranz-Saez, R. (2004) Follicular Lymphoma International Prognostic Index. Blood, 104(5): 1258-1265
Stamatopoulos, K., Kosmas, C., Belessi, C., Stavroyianni, N., Kyriazopoulos, P., Papadaki, T. (2000) Molecular insights into the immunopathogenesis of follicular lymphoma. Immunol Today, 21(6): 298-305